Xiangxue Pharmaceutical Co Ltd. Stock Analysis 300147.SZ

Xiangxue Pharmaceutical Co., Ltd. engages in the production, sale of modern traditional Chinese medicine are supplemented by medical equipment and other businesses. The company is headquartered in Guangzhou, Guangdong. The company went IPO on 2010-12-15. The firm operates five segments. The Pharmaceutical Manufacturing segment produces pharmaceutical products, including Chinese patent medicines (antiviral oral liquid, indigowoad root granules and Exocarpium Citri Reticulatae series), Chinese herbal medicines, and chemical medicines. The chemical medicines are used in oral and pharyngeal inflammation, hypertension, angina pectoris, colds and fevers. The Pharmaceutical Distribution segment is engaged in the distribution of Chinese herbal medicines, pharmaceutical markets, and blood products. The Medical Device segment mainly produces Baiyun medical glue and Gaoxun medical catheters. The Others segment includes T-cell immunotherapy, used to treat tumors and liver cancer. The firm distributes its products in domestic market.